What pharmacologic options are appropriate for treating insomnia in an adult with established cardiac disease (e.g., coronary artery disease, heart failure, arrhythmia, or hypertension)?

Medications for Insomnia in Patients with Heart Disease

For adults with established cardiac disease and insomnia, low-dose doxepin (3–6 mg) or ramelteon (8 mg) are the safest first-line pharmacologic options after initiating Cognitive Behavioral Therapy for Insomnia (CBT-I), while benzodiazepines should be avoided due to increased risk of heart failure rehospitalization and cardiac mortality.

Mandatory First-Line: Cognitive Behavioral Therapy for Insomnia (CBT-I)

• All patients with chronic insomnia and cardiac disease must receive CBT-I before or alongside any medication, as it provides superior long-term efficacy with sustained benefits after discontinuation and does not carry cardiovascular risks. 1

• Core CBT-I components include stimulus control (use bed only for sleep, leave bed if unable to sleep within 20 minutes), sleep restriction (limit time in bed to actual sleep time plus 30 minutes), relaxation techniques, and cognitive restructuring of maladaptive sleep beliefs. 1

• CBT-I can be delivered via individual therapy, group sessions, telephone-based programs, web-based modules, or self-help books—all formats demonstrate comparable effectiveness. 1

Preferred Pharmacologic Options for Cardiac Patients

First-Line: Low-Dose Doxepin

• Low-dose doxepin 3–6 mg is the preferred first-line hypnotic for sleep-maintenance insomnia in cardiac patients, reducing wake after sleep onset by 22–23 minutes with minimal anticholinergic effects at hypnotic doses and no abuse potential. 1, 2

• Start doxepin 3 mg at bedtime; if insufficient after 1–2 weeks, increase to 6 mg maximum. 1

• Doxepin has no quinidine-like cardiac effects (unlike tricyclic antidepressants at higher doses) and is safe in patients with coronary artery disease, heart failure, and arrhythmias. 3

First-Line: Ramelteon

• Ramelteon 8 mg is recommended for sleep-onset insomnia in cardiac patients, particularly those with substance use history, as it has no abuse potential, is not DEA-scheduled, causes no withdrawal symptoms, and does not impair next-day cognitive or motor performance. 1, 2

• Ramelteon has no cardiovascular contraindications and does not cause respiratory depression, making it safe across all cardiac conditions including heart failure and COPD. 1

Second-Line Options (If First-Line Fails)

Orexin Receptor Antagonists

• Suvorexant 10 mg reduces wake after sleep onset by 16–28 minutes through orexin-receptor antagonism and carries lower risk of cognitive and psychomotor impairment than benzodiazepine-type agents. 1, 4

• Suvorexant has no documented adverse cardiovascular effects and may be considered when doxepin or ramelteon are ineffective. 4

Non-Benzodiazepine Hypnotics (Z-Drugs)

• Eszopiclone 2–3 mg (1 mg if age ≥65 years) or zolpidem 10 mg (5 mg if age ≥65 years) may be used for combined sleep-onset and maintenance insomnia, but carry higher risks of complex sleep behaviors, falls, and cognitive impairment compared to doxepin. 1, 2

• In heart failure patients specifically, Z-drugs (zolpidem, zopiclone, eszopiclone) are associated with significantly lower risk of rehospitalization for heart failure compared to benzodiazepines (hazard ratio for benzodiazepines: 1.530; 95% CI: 1.025–2.284). 5

Medications to Absolutely Avoid in Cardiac Patients

Benzodiazepines (Contraindicated)

• Benzodiazepines (lorazepam, temazepam, clonazepam, diazepam) are contraindicated in heart failure patients, as they are independently associated with increased rehospitalization for heart failure (HR 1.530) and cardiac death compared to Z-drugs. 5

• Traditional benzodiazepines cause respiratory depression, worsen sleep apnea (common in heart failure), increase fall risk leading to fractures, and have higher dependence potential than alternatives. 1, 5

• Benzodiazepines have long half-lives leading to drug accumulation, prolonged daytime sedation, and cognitive impairment—particularly dangerous in elderly cardiac patients on multiple medications. 1, 6

Other Contraindicated Agents

• Over-the-counter antihistamines (diphenhydramine, doxylamine) are contraindicated due to strong anticholinergic effects causing confusion, urinary retention, tachycardia, falls, and daytime sedation—especially hazardous in patients with arrhythmias or heart failure. 1, 2

• Antipsychotics (quetiapine, olanzapine) must not be used for insomnia in cardiac patients due to weak efficacy evidence, significant metabolic side effects (weight gain, diabetes, dyslipidemia worsening cardiovascular risk), QTc prolongation, and increased mortality in elderly patients. 1, 6

• Trazodone is not recommended for primary insomnia as it yields only ~10-minute reduction in sleep latency with no improvement in subjective sleep quality, and adverse events occur in ~75% of older adults. 1

Cardiac-Specific Considerations

Arrhythmia Patients

• Avoid medications that prolong QTc interval (antipsychotics, high-dose tricyclic antidepressants). Low-dose doxepin (3–6 mg) does not carry this risk. 3

• Ramelteon and suvorexant have no documented arrhythmogenic effects and are safe in patients with atrial fibrillation or ventricular arrhythmias. 1, 4

Heart Failure Patients

• Insomnia in heart failure is often multifactorial: nocturnal dyspnea, orthopnea, paroxysmal nocturnal dyspnea, nocturia, and central sleep apnea contribute to sleep disruption. 7, 8

• Optimize heart failure management first (ACE inhibitors, beta-blockers, diuretics) as these medications improve cardiac performance and may reduce central sleep apnea severity, indirectly improving sleep quality. 8

• Screen for sleep apnea before prescribing any sedating medication; polysomnography is indicated if excessive daytime sleepiness is present, as sedatives can worsen respiratory depression in undiagnosed sleep apnea. 1, 2

• Avoid benzodiazepines entirely in heart failure patients due to documented increased rehospitalization and mortality risk. 5

Hypertension Patients

• Insomnia itself is a causal risk factor for hypertension development and cardiovascular events through autonomic imbalance, HPA-axis activation, and inflammation. 9

• Ramelteon and low-dose doxepin do not adversely affect blood pressure control, unlike some antidepressants at higher doses. 1, 3

Coronary Artery Disease Patients

• Sleep disturbances are present in 79.2% of post-PCI patients with coronary artery disease, and poor sleep quality is associated with worse cardiovascular outcomes. 10

• Mirtazapine, nefazodone, or trazodone may be considered if comorbid depression exists, as they lack the quinidine-like effects of tricyclic antidepressants that can worsen arrhythmias. 3

Treatment Algorithm for Cardiac Patients with Insomnia

Step 1 (Week 0): Initiate CBT-I Immediately

• Start stimulus control, sleep restriction, and sleep hygiene education for all cardiac patients with insomnia. 1

• Optimize cardiac medications (ACE inhibitors, beta-blockers) as these may improve sleep by reducing nocturnal symptoms. 8

• Screen for and treat sleep apnea if excessive daytime sleepiness, witnessed apneas, or refractory hypertension are present. 1, 2

Step 2 (Week 2–4): Add First-Line Pharmacotherapy If CBT-I Insufficient

• For sleep-onset insomnia: ramelteon 8 mg at bedtime. 1, 2

• For sleep-maintenance insomnia: low-dose doxepin 3 mg at bedtime (increase to 6 mg after 1–2 weeks if needed). 1, 2

• For combined sleep-onset and maintenance insomnia: start with doxepin 3–6 mg, as it addresses both components. 1

Step 3 (Week 4–6): Switch to Second-Line If First-Line Fails

• If ramelteon or doxepin ineffective after 2 weeks at therapeutic dose, switch to suvorexant 10 mg. 1, 4

• If suvorexant fails, consider eszopiclone 2 mg (1 mg if age ≥65 years) or zolpidem 5–10 mg (5 mg if age ≥65 years), but only after documenting failure of safer alternatives. 1, 5

Step 4 (Week 6+): Reassess and Taper

• Reassess every 2–4 weeks to evaluate sleep-onset latency, total sleep time, nocturnal awakenings, daytime functioning, and adverse effects. 1

• Use the lowest effective dose for the shortest duration possible; FDA labeling limits hypnotics to ≤4 weeks for acute insomnia. 1

• Taper medications gradually while maintaining CBT-I techniques to sustain sleep improvements. 1

Critical Safety Monitoring in Cardiac Patients

• Screen for complex sleep behaviors (sleep-driving, sleep-walking, sleep-eating) at every visit; discontinue medication immediately if these occur. 1

• Monitor for falls, cognitive impairment, and morning sedation—particularly dangerous in elderly cardiac patients on anticoagulation. 1

• Avoid combining multiple sedating agents (e.g., adding a benzodiazepine to doxepin), as this markedly increases risk of respiratory depression, falls, and cognitive impairment. 1

• Educate patients to take hypnotics only when ≥7 hours remain before planned awakening, avoid alcohol, and report any next-day impairment. 1

Common Pitfalls to Avoid

• Do not prescribe benzodiazepines to heart failure patients—this directly increases rehospitalization and mortality risk. 5

• Do not initiate pharmacotherapy without concurrent CBT-I, as behavioral therapy provides more durable benefits and is mandated as first-line treatment. 1

• Do not use adult dosing in elderly cardiac patients; age-adjusted dosing (e.g., zolpidem ≤5 mg, eszopiclone ≤2 mg, doxepin 3 mg) is essential to reduce fall risk. 1

• Do not overlook sleep apnea screening in cardiac patients, as undiagnosed sleep apnea worsens cardiovascular outcomes and contraindicates sedating medications. 1, 2

• Do not continue hypnotics beyond 4 weeks without documented rationale and regular reassessment, as long-term safety data are insufficient. 1